Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 50,56€(+34,29%). Der Median liegt bei 50,77€(+34,85%).
Kaufen | 18 |
Halten | 3 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 3 / 18 |
Levermann-Strategie | -4 / 13 |
News
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $44.00 per share and the pre-funded warrants are being sold at a public offering price of $43.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock, less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Kymera has granted the underwriters a 30-day option to purchase up to an additional 855,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds to Kymera from the offering are expected to be approximately $250.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Kymera, excluding the exercise of any pre-funded warrants and assuming no exercise of the underwriters' option to purchase additional shares. All of the securities being sold in this offering are being offered by Kymera. The offering is expected to close on June 30, 2025, subject to the satisfaction of customary closing conditions.» Mehr auf globenewswire.com
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera's shares drop as Sanofi ends KT-474 development, but Gilead's oncology deal remains positive.» Mehr auf zacks.com
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 20,43 Mio | 114,32% |
Bruttoeinkommen | 20,43 Mio | 114,32% |
Nettoeinkommen | −60,62 Mio | 34,74% |
EBITDA | −58,66 Mio | 34,62% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 2,45 Mrd€ |
Anzahl Aktien | 65,12 Mio |
52 Wochen-Hoch/Tief | 45,46€ - 16,59€ |
Dividenden | Nein |
Beta | 2,07 |
KGV (PE Ratio) | −14,68 |
KGWV (PEG Ratio) | 3,35 |
KBV (PB Ratio) | 4,50 |
KUV (PS Ratio) | 48,79 |
Unternehmensprofil
Kymera Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung und Entwicklung neuartiger niedermolekularer Therapeutika konzentriert, die selektiv krankheitsverursachende Proteine abbauen, indem sie sich das körpereigene natürliche Proteinabbausystem zunutze machen. Das Unternehmen entwickelt das IRAK4-Programm, das sich in der klinischen Phase I zur Behandlung von immunologischen Entzündungskrankheiten wie Hidradenitis suppurativa, atopischer Dermatitis, Makrophagenaktivierungssyndrom, allgemeiner pustulöser Psoriasis und rheumatoider Arthritis befindet; IRAKIMiD-Programm zur Behandlung des MYD88-mutierten diffusen großzelligen B-Zell-Lymphoms; STAT3-Programm zur Behandlung von hämatologischen Malignomen und soliden Tumoren sowie von Autoimmunerkrankungen und Fibrose; und MDM2-Programm zur Behandlung von hämatologischen Malignomen und soliden Tumoren. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in Watertown, Massachusetts.
Name | KYMERA THERAP.INC. -,0001 |
CEO | Nello Mainolfi |
Sitz | Watertown, ma USA |
Website | |
Industrie | Nahrungsmittel |
Börsengang | |
Mitarbeiter | 208 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | KYMR |
Assets entdecken
Shareholder von KYMERA THERAP.INC. -,0001 investieren auch in folgende Assets